Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Yi Wen Huang, Albert Qin, Chan Yen Tsai, Pei Jer Chen

研究成果: 雜誌貢獻回顧型文獻同行評審

摘要

Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e., once every two to four weeks, compared to conventional pegylated interferon products, which have multiple isomers and are administered weekly. It was approved for the long-term treatment of polycythemia vera, an MPN, and has been included in the NCCN clinical practice guidelines for this indication. Ropeginterferon alfa-2b has demonstrated efficacy and showed a favorable safety profile for the treatment of chronic viral hepatitis in several clinical studies. In this article, we review its pharmacokinetics and available clinical data and suggest that ropeginterferon alfa-2b administered once every two weeks can serve as a new treatment option for patients with chronic viral hepatitis, including chronic hepatitis B, C, and D.

原文英語
文章編號1128
期刊Viruses
14
發行號6
DOIs
出版狀態已發佈 - 6月 2022

ASJC Scopus subject areas

  • 傳染性疾病
  • 病毒學

指紋

深入研究「Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis」主題。共同形成了獨特的指紋。

引用此